During the evaluation of angiogenesis, decreased CD31 (a marker of vascular endothelial cells) and ɑ-SMA (a marker of pericytes) expression levels were observed after neoadjuvant therapy, thus confirming the antiangiogenic effect in tumours (Fig. 5A, B). The gene discussed is PECAM1; the disease is neoplasm.